Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Retained Earnings for 8 consecutive years, with -$1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 38.38% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 38.38% YoY), while the FY2025 annual figure was $1.8 million, up 100.24% from the prior year.
• Retained Earnings retreated to -$1.1 billion in Q1 2026 per KYMR's latest filing, from $1.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $1.8 million in Q4 2025 and bottomed at -$1.1 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$424.6 million across 5 years, with a median of -$383.8 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 58050.0% — and 2025, when it soared 113.29%.
• Kymera Therapeutics' Retained Earnings stood at -$383.8 million in 2022, then slumped by 38.29% to -$530.8 million in 2023, then sank by 42.18% to -$754.6 million in 2024, then jumped by 100.24% to $1.8 million in 2025, then slumped by 63155.56% to -$1.1 billion in 2026.
• Business Quant data shows KYMR's Retained Earnings at -$1.1 billion in Q1 2026, $1.8 million in Q4 2025, and -$979.0 million in Q3 2025.